DCI Donor Services, Inc. Expands Its Commitment to the CLEARANT PROCESS(R) With Agreement to Use the Recently-Launched Clearant Sterilization Service.

LOS ANGELES -- Clearant, Inc. (OTCBB: CLRI), the developer of the patent-protected CLEARANT PROCESS(R) for pathogen inactivation, announced today that DCI Donor Services, Inc., a leading tissue bank with eight affiliated service organizations throughout the United States, has signed an agreement to expand its commitment to the Clearant Process through the use of Clearant's new Clearant Sterilization Service.

DCI distributes, directly and through their third-party partner organizations, approximately 23,000 soft tissue and bone allografts annually. DCI will utilize Clearant's Sterilization Service on a variety of human-sourced soft-tissue and bone allograft implants.

Under an existing agreement with Clearant, DCI currently applies the CLEARANT PROCESS(R) to their soft tissue allografts in their processing facility. Through the Clearant Sterilization Service contract, DCI can outsource to Clearant the irradiation of hard and soft tissue allografts under Clearant's patented process. This outsourcing allows DCI to better utilize internal resources as well as benefit from economies of scale that Clearant can achieve.

In the near future, DCI will expand its current use of the CLEARANT PROCESS(R) to sterilize its private label bone implants as a part of the adoption of the Clearant Sterilization Service. The Clearant Sterilization Service also provides DCI the ability to expand its availability of safer implants to include those distributed by its third party distributors.

"Surgeons have embraced the safer soft tissue allografts that are now offered by DCI that have been treated by the CLEARANT PROCESS," said Kelli Orr, Executive Director of DCI Donor Services, Inc. "We are very excited about the convenience offered by the Clearant Sterilization Service. In the near future, we plan to offer private label bone implants sterilized through the Clearant Sterilization Service; these implants will be distributed directly to surgeons. We expect that the added convenience of the Clearant Sterilization Service will make it more convenient for us to offer the highest level of tissue sterility to our third party distribution partners as well."

"We are thrilled to have DCI expand their use of the CLEARANT PROCESS to include their future bone implant business," said Alain Delongchamp, Chief Executive Officer of Clearant, Inc. "DCI's decision to incorporate the Clearant Sterilization Service into their processing operations is yet another example of the value that our new service brings to the tissue processing industry."

Clearant currently has eight devitalized human tissue bank customers under contract. This DCI agreement increases the number of Clearant Sterilization Service contracts to three.

About Clearant, Inc.

Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant, Inc. has developed the patent-protected CLEARANT PROCESS(R), designed to substantially reduce all types of pathogens in biological products while maintaining a high degree of the underlying protein. Various sterilization methods on the market today only kill specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The CLEARANT PROCESS(R) can substantially reduce all types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container.

About DCI Donor Services

The mission of DCI Donor Services is to support families in member communities who have sustained the loss of a loved one by providing an opportunity for the donation of anatomical gifts and by facilitating the recovery and transplantation of these gifts to individuals in need. DCI currently recovers and processes tissue from approximately 1,000 donors annually, resulting in the processing of approximately 23,000 transplant allografts. Additionally, they provide tissue to researchers within their recovery service area to promote the advancement of scientific investigation and medical therapy.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC. For more information about Clearant, Inc., please see www.clearant.com.